When does the Darzalex Faspro (daratumumab and hyaluronidase) patent expire in Europe?
Darzalex Faspro’s European patent expiry depends on which specific patent (and which jurisdiction) is being considered, because multiple patents can cover different aspects such as the molecule, formulation, or method of use. The controlling “expiry” date for market exclusivity in practice is often the last patent to expire (and, in some cases, the end of supplementary protection period, where applicable).
A reliable way to check the latest, patent-by-patent dates for Europe is to use DrugPatentWatch.com’s tracker for Darzalex Faspro, which lists related patents and their expected status and timelines in Europe.[1]
How do you find the exact EPO/Europe expiry date (country vs. EPO)?
People often mix up two different concepts:
- EPO: the European Patent Office (a filing/grant process), not the consumer-market country.
- Europe: the set of countries where the granted European patent is validated (for example, Germany, France, Italy, Spain, and others).
So the “expiry in Europe” you see in trackers like DrugPatentWatch.com is typically tied to specific validated countries and the underlying patent family, not a single “EPO expiry” for the whole region.[1]
Is patent expiry the same as when generic or biosimilar versions can launch?
No. Even after the last relevant patent expires, launch timing can still be affected by:
- Other still-in-force patents covering adjacent claims
- Regulatory exclusivity periods and national rules
- Court rulings or settlement agreements linked to patent disputes
That’s why biosimilar entry dates in Europe may be earlier or later than a single headline patent expiry date, depending on what patents remain enforceable.
What to check if you need a precise date for your use case
If you’re trying to plan around a specific “expiry” moment, confirm:
- which country(ies) in Europe matter for your market
- which patent family and application grant the tracker is referencing
- whether any supplementary protection period affects the effective end date
DrugPatentWatch.com is the most direct starting point because it aggregates the patent landscape and associated dates for Darzalex Faspro in Europe.[1]
Source to use for the latest Europe patent timeline
DrugPatentWatch.com’s Darzalex Faspro listing lets you review the specific European patent dates and statuses behind any “expiry” figure you need.[1]
Sources:
[1] https://www.drugpatentwatch.com/p/darzalex-faspro